EGRP News Flash - January 15, 2010

This NEWS FLASH from the National Cancer Institute's (NCI) Epidemiology and Genetics Research Program (EGRP) brings you news about the reissuance of the following Program Announcements (PAs) that it is sponsoring:

Return to Top

Epigenetic Approaches in Cancer Epidemiology

EGRP is sponsoring two PAs on Epigenetic Approaches in Cancer Epidemiology to encourage research applications that propose to evaluate profiles of methylation, histone modifications, and microRNA (miRNA), and their association with risk of developing cancer in different populations. The overarching goal of these PAs is to provide support for population-based studies to define the role of epigenetic markers (methylation, histone modifications, and miRNA profiles) and changes in these markers in understanding cancer etiology.

Specific research areas of interest include, but are not limited to, the following:

  • Determinations of the roles of physical, chemical, and infectious agents and behavioral factors in the changes in types and levels of DNA methylation, histone modifications, and miRNA in human populations of different races and ethnicities;
  • Determination of the role(s) of epigenetic changes in the risk of cancer in human populations; and
  • Identification of genetic, environmental, and host susceptibility factors that modify the risk of cancer associated with epigenetic alterations in different races and ethnic groups.

These PAs use the Research Project (R01) and Exploratory/Developmental (R21) grant mechanisms.

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch.

Access the NIH Guide for Grants and Contracts:

Return to Top

Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis

Two PAs cosponsored by NCI's Division of Cancer Control and Population Sciences (DCCPS) and its Division of Cancer Treatment and Diagnosis (DCTD) have been reissued to encourage applications for research projects to develop, apply, and evaluate new and existing cancer risk and prognostic prediction models for use by researchers, clinicians, and the general public. These PAs are to support research to develop new and refine existing cancer risk prediction, prognostic, and response to therapy models, and validate them in appropriate populations. In particular, the PAs provide a mechanism through which investigators can address two major challenges in model development, namely integrating diverse types of data and ensuring adequate validation.

The parallel PAs use the Research Project (R01) and Exploratory/Developmental (R21) grant mechanisms.

EGRP Contacts: Andrew N. Freedman, Ph.D., Chief, Clinical and Translational Epidemiology Branch, and Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch.

Access the NIH Guide for Grants and Contracts:

Return to Top